- Serine Proteases
- Accession Number
Peptide hydrolases that contain at the active site a SERINE residue involved in catalysis.
Drug Drug Description Alteplase A recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Urokinase A low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines. Reteplase A purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Ocriplasmin A proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula. Thrombin alfa A platelet activating factor used to treat minor bleeding. Ancrod An anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country. Serotonin For temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product. Anistreplase A form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. Tenecteplase A modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. Coagulation factor VIIa Recombinant Human A form of recombinant human coagulation Factor VII used to treat hemophilia A and B. Desmoteplase Investigated for use/treatment in cerebral ischemia and strokes. Fibrinolysin Fibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas. Talactoferrin alfa Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers. Lanoteplase Investigated for use/treatment in myocardial infarction. Amediplase Investigated for use/treatment in myocardial infarction and thrombosis. Batroxobin No approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously. Chymotrypsin A digestive enzyme supplement used as supportive therapy to manage the side effects associated with conventional chemotherapy, radiotherapy, and hormone therapy. Sutilain Sutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular... Trypsin A naturally occurring proteolytic enzyme found in the digestive tract of mammals. Used clinically in combination with bromelain and rutosides in the treatment of some inflammatory conditions. Thrombin A coagulation factor used to stop bleeding during surgery. Rusalatide acetate Chrysalin has been used in trials studying the treatment of Radius Fracture. Vonapanitase Vonapanitase is under investigation for the treatment of Chronic Kidney Disease. Vatreptacog alfa Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors. Monteplase Monteplase has been used in trials studying the treatment of Pulmonary Embolism. Kallidinogenase Not Annotated Saruplase Not Annotated Andexanet alfa A recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban. Marzeptacog alfa (activated) Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia). Nattokinase Nattokinase is under investigation in clinical trial NCT00749801 (Efficacy and Safety of Geneferm Nattokinase). Coagulation factor XIa Coagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency). Lactoferrin Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).
- Drugs & Drug Targets